Cardioprotection thread, page-565

it’s important to note that the Race team and world class cardio-oncologists have have ok’d the CPACS combo. They have access to the data, we don’t! yet still they are confident enough for a P2 and constant buying on market by DrT.

Next step RC220 release this month then straight into clinical validation. Its not just a safety trial it’s proof of concept in a basket trial and a new drug class. Triple validation, cardio protect, FTO and multiple cancer synergy.

Is the science works where does this fit in commercially? Well my view is DACS-F (Decitabine Anti-Cancer Synergy+FTO) is being severely underestimated. If DACS-F really flips a liquid tumour only therapy to solid tumour multi-indication who else would want this in the hands of their competitors.

Expect traction on DACS-F to progress in the next 12 months, if Astex liked AML what will they think on DACS-F?

Watch this space - best of luck!